Sitagliptin compared with the Sulfonylurea Glimepiride provides similar efficacy with less Hypoglycemia and no weight gain when added to ongoing Metformin therapy in patients with…

Question: Current guidelines recommend the addition of another antihyperglycemic agent when glycemic control is not achieved with metformin monotherapy. Sulfonylureas are the most common antihyperglycemic agents used in combination with metformin among patients who do not achieve or maintain glycemic control on metformin alone. In previous studies, the DPP-4 inhibitor sitagliptin (SITA) significantly improved glycemic control and was well tolerated when added to ongoing metformin monotherapy. The current study compared the efficacy and safety of SITA with the commonly-used sulfonylurea glimepiride (GLIM). Method…